ASC-09 / J&J, Ascletis - LARVOL DELTA

Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease. (PubMed, Chem Phys) - "In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 M were investigated. It is found that most of the selected drug molecules bind stably to the COVID-19 M from the molecular dynamics simulation. Moreover, the MM/PBSA free energy calculations suggest that lopinavir with positive charge might be most active against COVID-19 M."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective. (PubMed, Future Sci OA) - "Our study further implicated two important rings in the structure of RVT as a possible chemical culprit in its therapeutic activity. Although there are conflicting clinical results on the therapeutic potency of RVT in the treatment of coronavirus disease 2019, our findings provided molecular insight into the binding mechanism of TMC-310911 and RVT with SARS-CoV-2 and SARS-CoV main proteases."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Ascletis Pharmaceuticals Co., Ltd.; Not yet recruiting ➔ Completed; Trial completion date: Jan 2024 ➔ Dec 2020

Clinical • Trial completion • Trial completion date

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. (PubMed, Protein J) - "Structural and energetic analyses involving root-mean-square deviation, binding energy per-frame, center-of-mass distance, and hydrogen bond length demonstrated the stability of TMC-310911 and ritonavir inside the M's active site over the 50 ns MD simulation. This study sheds light on HIV protease drugs as prospective SARS-CoV-2 M inhibitors."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. (PubMed, Sci Rep) - "Among them, saquinavir and three other investigational drugs aclarubicin, TMC-310911, and faldaprevir could be suggested as potential 3CL inhibitors. We recommend further experimental investigation of these compounds."

Journal • Infectious Disease • Novel Coronavirus Disease

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Clinical • New P1 trial

Drug repurposing using computational methods to identify therapeutic options for COVID-19. (PubMed, J Diabetes Metab Disord) - "According to the results, glecaprevir, paritaprevir, simeprevir, ledipasvir, glycyrrhizic acid, TMC-310911, and hesperidin showed highly favorably free binding energies with all tested target proteins. The above-mentioned drugs can be regarded as candidates to treat COVID-19 infections, but further study on the efficiency of these drugs is also necessary."

Journal • Infectious Disease • Novel Coronavirus Disease • TMPRSS2

The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking. (PubMed, Comb Chem High Throughput Screen) - "Our in silico docking results have been confirmed by current reports from clinical settings through the citation of suitable experimental in vitro data available in the published literature."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology

Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. (PubMed, J Biomol Struct Dyn) - "In the present study, we have chosen two clinical trial drugs against HIV-1 protease namely, TMB607 and TMC310911 to use as the inhibitors of SARS-CoV-2 main protease (M) enzyme. This in silico study proves that the TMB607 molecule binds strongly with the SARS-CoV-2 M enzyme and it may be suitable for the drug repurposing of COVID-19 and further drug designing. Communicated by Ramaswamy H. Sarma."

Clinical • Journal • Gene Therapies • Infectious Disease • Novel Coronavirus Disease

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia (clinicaltrials.gov) - P3; N=60; Recruiting; Sponsor: Tongji Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection (clinicaltrials.gov) - P=N/A; N=160; Not yet recruiting; Sponsor: First Affiliated Hospital of Zhejiang University

Clinical • New trial

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia (clinicaltrials.gov) - P3; N=60; Not yet recruiting; Sponsor: Tongji Hospital

Clinical • New P3 trial